Cambios de dirección y actualización de resultados del año fiscal 23
Novacyt SA
("Novacyt", la "Compañía" o el "Grupo")
Directorate changes and full year 2023 results update
Lyn Rees appointed CEO
Dr. Joanne Mason, CSO, to join the Board
París, Francia, y Eastleigh y Manchester, Reino Unido - 11 de abril de 2024 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces changes to the Board of Directors. Lyn Rees, Executive Director, has been appointed Chief Executive Officer and James McCarthy will step down from the Board as Acting CEO, both effective from 1 May 2024. James will remain with the Company for a period of time to officiate a smooth transition.
Lyn is a seasoned healthcare executive with over 28 years' global leadership and commercial experience and a proven track record of successfully building/scaling companies. He became CEO of Yourgene Health plc in 2018 where he led the group through four acquisitions and the sale to Novacyt in 2023. Prior to this, he spent 19 years at British Biocell International (now BBI Group), nine of which as Group CEO, where he completed and successfully integrated seven acquisitions.
Additionally, Dr Joanne Mason, the Company's Chief Scientific Officer, will join the Novacyt Board as an Executive Director effective from 1 May 2024 subject to shareholder approval at the Company's Annual General Meeting and, Dr Andrew Health, Non-Executive Director will retire from the Board of Directors effective 1 May 2024.
Joanne is a leading molecular biologist, with over 22 years' experience having worked in senior positions both in industry and at prominent research institutes. As Chief Scientific Officer at Yourgene Health, she led the development of next generation molecular diagnostics. Prior to this, she held lead scientific roles at Cambridge Epigenetix, Genomics England and Oxford Biomedical Research Centre. She has also acted as an adviser on a number of boards and committees, including the DOH Rare Disease Policy board, MHRA Genomics for Diagnosis forum and UK NEQA. Joanne holds a PhD from the University of Cambridge in Molecular and Cellular Biology.
James Wakefield, presidente no ejecutivo, comentó: "On behalf of the Board I would like to thank James and Andrew for their hard work and significant contribution to the Group, and wish them both well in their future endeavours. We are delighted to welcome Jo to the Board and Lyn as CEO - they have been instrumental in the seamless integration of Novacyt and Yourgene and will be key drivers in the accelerated growth of the enlarged Group portfolio. Lyn has significant global leadership and commercial expertise, and I am confident that he is the right person to lead the Group as it continues to execute its growth strategy and generate value for shareholders."
Commenting, Lyn Rees, Executive Director and incoming CEO, said: "I am excited to have the opportunity to lead Novacyt in its next stage of development. The molecular diagnostics market is experiencing rapid growth, driven by the continued demand for fast and accurate diagnostics and with our strong portfolio of molecular assays and instruments combined with our leading expertise I believe we are well placed to capture this. I would like to thank James for his support since I joined the Company and look forward to working with the entire team as we continue to deliver our strategy."
Actualización de resultados del año fiscal 23
Under Euronext Growth reporting requirements, the Company is required to publish its annual accounts within four months of its year-end.
The publication of the annual results for the year ended 31 December 2023, initially scheduled for release by 30 April 2024, has been postponed and will be published by the end of May 2024. This is due to the time required to integrate the accounts of Yourgene Health, acquired towards the end of the year, into Novacyt's consolidated results.
Unaudited revenue for FY23 remains in line with the prior guidance at £11.6m.
Further information on Dr Joanne Mason
Dr Joanne Nicola Mason (née Gooch) (aged 49) has held the following directorships or partnerships in the past five years:
Directorios / asociaciones actuales | Directorios/sociedades anteriores (últimos cinco años) |
Yourgene Genomic Services Ltd
Yourgene Salud Reino Unido Ltd | Yourgene Health Limited (formerly Yourgene Health plc) |
Dr Mason does not hold any shares in the Company.
Contacto
Novacyt SA | https://novacyt.com/investors | |||
James McCarthy, director ejecutivo interino | A través de Walbrook PR | |||
Steve Gibson, director financiero
| ||||
SP Angel Corporate Finance LLP (Asesor designado y Broker) | 44 0 20 3470 0470 | |||
Matthew Johnson / Charlie Bouverat (Finanzas corporativas) Vadim Alexandre / Rob Rees (Corretaje corporativo) | ||||
Deutsche Numis (Articulación Broker) | 44 0 20 7260 1000 | |||
Freddie Barnfield/Duncan Monteith/Michael Palser | ||||
Allegra Finance (Patrocinador de anuncios francés) Rémi Durgeto / Yannick Petit | + 33 (1) 42 22 10 10 | |||
Walbrook PR (Relaciones Públicas y Relaciones Públicas Financieras) Stephanie Cuthbert / Paul McManus / El matrimonio de Phillip / Alice Woodings | +44 (0) 20 7933 8780 o GME@dhr-rgv.com +44 (0) 7796 794 / +663 (44) 0 7980 +44 (0) 7867 984 / +082 (44) 0 7407 | |||
Sobre el Grupo Novacyt (www.novacyt.com)
Novacyt es un Empresa internacional de diagnóstico molecular que ofrece una amplia cartera de tecnologías y servicios integrados, centrados principalmente en la entrega de medicina genómica. La empresa desarrolla, fabrica y comercializa una gama de instrumentos y ensayos moleculares para ofrecer flujos de trabajo y servicios que permitan soluciones integrales perfectas, desde la muestra hasta el resultado, en múltiples sectores, incluidos la salud humana, la salud animal y el medio ambiente.
La Compañía se divide en tres segmentos de negocio:
Clínico | Amplia cartera de productos clínicos humanos. in vitro productos, flujos de trabajo y servicios de diagnóstico enfocados en tres áreas terapéuticas: · Salud Reproductiva: NIPT, Fibrosis Quística y otras pruebas rápidas de aneuploidías · Medicina de precisión: ensayo de genotipado DPYD · Enfermedades infecciosas: Winterplex, múltiplex panel de PCR respiratorio de invierno
|
Instrumentación | Portafolio de plataformas de preparación de muestras de ADN de selección de tamaño de próxima generación y rápidas. Máquinas de PCR, que incluyen: · Tecnología Ranger®: preparación automatizada de muestras de ADN y tecnología de enriquecimiento de objetivos MyGo: instrumentos de PCR cuantitativa (qPCR) en tiempo real
|
Solo para uso en investigación | Gama de servicios para la industria de la investigación: · Diseño, fabricación y suministro de ensayos y flujos de trabajo de qPCR de alto rendimiento para su uso en salud humana, agricultura, veterinaria y medio ambiente, para apoyar a las organizaciones de salud globales y la industria de la investigación. · Servicios de investigación farmacéutica: secuenciación del genoma completo (WGS) / secuenciación del exoma completo (WES) |
Novacyt tiene su sede en Vélizy (Francia) y oficinas en el Reino Unido (en Stokesley, Eastleigh y Manchester), Taipei, Singapur, Estados Unidos y Canadá y tiene presencia comercial en más de 65 países. La Compañía cotiza en el mercado AIM de la Bolsa de Valores de Londres ("NCYT") y en la Bolsa de Valores de París Euronext Growth ("ALNOV").
Para obtener más información, consulte el sitio web: www.novacyt.com
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.